51719-69-8

Usage

Aromatic compound

Yes

Number of bromine atoms

Three

Benzene ring

Present

Methyl group position

5th

Main uses

a. Organic synthesis
b. Intermediate in pharmaceuticals and agrochemicals production
c. Building block in synthesis of various organic compounds
d. Reagent in chemical reactions
e. Research laboratories for chemical properties and potential applications

Applications

a. Pharmaceutical industry
b. Agrochemical industry
c. Organic compound synthesis
d. Chemical research and development

Upstream product

• 556-96-7 5-bromo-1,3-xylene 
• 94-36-0 dibenzoyl peroxide 

Downstream Products

• 871116-91-5 2-(3-bromo-5-methylphenyl)acetonitrile 
• 1611-92-3 3-bromo-5-methylbenzaldehyde 
• 195209-24-6 1-bromo-3,5-bis(diethoxyphosphorylmethyl)benzene 
• 1160499-23-9 C₁₈H₁₈N₄ 
• 1161361-97-2 2-(3-bromo-5-methylphenyl)propanenitrile 
• 1160500-07-1 2-methyl-2-(3-methyl-5-(1H-pyrazolo[3,4-b]pyridin-4-yl)phenyl)butan-1-amine 
• 1427330-94-6 2-[2,4-difluoro-3-[[3-(3-fluorophenyl)-5-methyl-phenyl]methylamino]phenoxy]acetic acid 
• 1427406-76-5 C₂₅H₂₄F₃NO₃ 
• 1427406-75-4 isopropyl 2-[3-[(3-bromo-5-methyl-phenyl)methylamino]-2,4-difluorophenoxy]acetate 
• 1177558-71-2 tert-butyl (3-bromo-5-cyanobenzyl)carbamate 

Relevant academic research and scientific papers

New fluorescent tetraphenylporphyrin-based dendrimers with alkene-linked fluorenyl antennae designed for oxygen sensitization

The design of porphyrin-based dendrimers featuring conjugated fluorenyl dendrons via alkene spacers allows evaluating the importance of the role of these spacers on the optical properties of interest. In the continuation of previous studies, a second-gene

Novel phenanthrene compounds, a method of making the same and organic electronic devices using the same

The present invention relates to novel phenanthrene compounds having excellent luminous efficiency and lifespan, a manufacturing method thereof, and an organic electronic device including the novel phenanthrene compounds. The novel phenanthrene compounds according to the present invention can form steric conformation, can improve performance through improvement of electronic density, also can improve performance by regulating the molecular weight and position of a functional group because the molecular weight of the compounds is low, and can minutely regulate luminous wavelength and improve performance according to types of the functional groups. As the result, the organic electronic device including the novel phenanthrene compounds has high brightness, excellent thermal resistance, long lifespan, and high efficiency.

Exploration of phenylpropanoic acids as agonists of the free fatty acid receptor 4 (FFA4): Identification of an orally efficacious FFA4 agonist

The long chain free fatty acid receptor 4 (FFA4/GPR120) has recently been recognized as lipid sensor playing important roles in nutrient sensing and inflammation and thus holds potential as a therapeutic target for type 2 diabetes and metabolic syndrome. To explore the effects of stimulating this receptor in animal models of metabolic disease, we initiated work to identify agonists with appropriate pharmacokinetic properties to support progression into in vivo studies. Extensive SAR studies of a series of phenylpropanoic acids led to the identification of compound 29, a FFA4 agonist which lowers plasma glucose in two preclinical models of type 2 diabetes.

ANILINE DERIVATIVES,THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION

The present invention relates to aniline derivatives, to their preparation and to their therapeutic application.

Regioisomerism in the synthesis of a chiral aminotetralin drug compound: Unraveling mechanistic details and diastereomer-specific in-depth NMR investigations

During chemical process development of a novel 2-aminotetralin derivative intended for use as an antidepressant, scrutiny of the byproduct present in the drug molecule revealed a set of regioisomers. Detailed studies showed that this impurity issue origin

Dual Pharmacophores - PDE4-Muscarinic Antagonistics

The present invention relates to novel compounds of Formula (I) and their use in the treatment of respiratory diseases, including anti-inflammatory and allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.

Dual Pharmacophores - PDE4-Muscarinic Antagonistics

The present invention is directed to novel compounds of Formula (I), pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of/and or prophylaxis of respiratory diseases, including antiinflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.

DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS

The present invention is directed to novel compounds of Formula's (I) - (VI), and pharmaceutically acceptable salts thereof, pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of and/or prophylaxis of respiratory diseases, including inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.

NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS

The invention is related to compounds of Formula (I) or a pharmaceutically acceptable salt, solvate, ester, and/ or phosphonate thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.

PROCESSES FOR PREPARING HIV REVERSE TRANSCRIPTASE INHIBITORS

Compounds of Formula (I): can be prepared by a multi-step process from compounds of Formula (II): wherein G is Cl, Br or I.